A team of scientists has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer. The discovery marks a critical step toward developing a potential new class of anti-cancer drugs that enhance the activity of a prevalent family of tumor suppressor proteins, the authors say.